Your search returned 6 results.

Sort
Results
1.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 28386990
Year: 2017
Citation:
  • Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
2.
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. MedStar authors:
  • Weissman, Neil J
PMID:
  • 22421927
Year: 2012
Citation:
  • Obesity. 20(7):1426-36, 2012 Jul.
Institution:
  • MedStar Heart & Vascular Institute
Medline publication type:
  • Journal Article
  • Randomized Controlled Trial
Form of publication:
  • Journal Article
All authors:
  • Anderson CM, Fidler MC, O'Neil PM, Raether B, Sanchez M, Shanahan WR, Smith SR, Weissman NJ, Zhang J
3.
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 29246950
Year: 2018
Citation:
  • Diabetes Care. 41(2):258-266, 2018 02.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
4.
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 31530665
Year: 2019
Citation:
  • Diabetes Care. 42(11):2108-2116, 2019 11.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Blonde L, Del Prato S, Frias J, Henry R, Ji C, Niemoeller E, Rosenstock J, Shehadeh N, Souhami E
5.
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 32139384
Year: 2020
Citation:
  • Diabetes Care. 43(5):940-947, 2020 05.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Butera NM, Camp AW, Cherrington A, Craig J, Fortmann SP, GRADE Research Group, Hollander PA, Krakoff J, Perez M, Phillips LS, Rasouli N, Sivitz WI, Tan MH, Tiktin M, Wexler DJ, Younes N
6.
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. MedStar authors:
  • Ratner, Robert E
PMID:
  • 23175674
Year: 2013
Citation:
  • Arteriosclerosis, Thrombosis & Vascular Biology. 33(2):393-9, 2013 Feb.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
Form of publication:
  • Journal Article
All authors:
  • Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Musi N, Ratner RE, Reaven PD, Saremi A, Schwenke DC, Stentz FB, Tripathy D
Pages

Powered by Koha